Dr. Awan Discusses Venetoclax in CLL

Farrukh Awan, MBBS
Published: Tuesday, Oct 03, 2017



Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Venetoclax has been approved for relapsed patients with CLL who have a 17p deletion. As a single agent, it is very effective, potent, and induces deep remissions, says Awan.

Based on its success, it is starting to be tested in combinations.
 


Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Venetoclax has been approved for relapsed patients with CLL who have a 17p deletion. As a single agent, it is very effective, potent, and induces deep remissions, says Awan.

Based on its success, it is starting to be tested in combinations.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Publication Bottom Border
Border Publication
x